|
|
Volumn 7, Issue 10, 2002, Pages 563-568
|
|
Discovery, innovation and the cyclical nature of the pharmaceutical business
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMLODIPINE;
AMLODIPINE BESYLATE;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ANTIDEPRESSANT AGENT;
ANTIFUNGAL AGENT;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
CALCIUM CHANNEL BLOCKING AGENT;
CITALOPRAM;
CLOMIPRAMINE;
DIHYDROPYRIDINE DERIVATIVE;
DILTIAZEM;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
FELODIPINE;
FLUOXETINE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
MACROLIDE;
MEVINOLIN;
MIBEFRADIL;
NIFEDIPINE;
PAROXETINE;
QUINOLINE DERIVED ANTIINFECTIVE AGENT;
SALBUTAMOL;
SALMETEROL;
SEROTONIN ANTAGONIST;
SEROTONIN UPTAKE INHIBITOR;
SERTRALINE;
SIMVASTATIN;
UNINDEXED DRUG;
VENLAFAXINE;
VERAPAMIL;
CARDIOTOXICITY;
DRUG INDUSTRY;
DRUG STRUCTURE;
HEALTH CARE;
HUMAN;
REVIEW;
ARTICLE;
DRUG DESIGN;
METHODOLOGY;
TIME;
DRUG DESIGN;
DRUG INDUSTRY;
TIME FACTORS;
|
|
EID: 0037092617
PISSN: 13596446
EISSN: None
Source Type: Journal
DOI: 10.1016/S1359-6446(02)02266-3 Document Type: Review |
|
Times cited : (16)
|
|
References (13)
|
